;PMID: 1700215 ;source_file_1754.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..46] = [t:0..46] ;1)sentence:[e:52..219] = [t:52..219] ;2)section:[e:223..283] = [t:223..283] ;3)section:[e:287..356] = [t:287..356] ;4)sentence:[e:360..475] = [t:360..475] ;5)sentence:[e:476..683] = [t:476..683] ;6)sentence:[e:684..811] = [t:684..811] ;7)sentence:[e:812..920] = [t:812..920] ;8)sentence:[e:921..1041] = [t:921..1041] ;9)sentence:[e:1042..1120] = [t:1042..1120] ;10)sentence:[e:1121..1276] = [t:1121..1276] ;11)section:[e:1280..1324] = [t:1280..1324] ;section 0 Span:0..46 ;J Cardiovasc Pharmacol. 1990 Sep;16(3):438-43. (SEC (FRAG (NNP:[0..1] J) (NNP:[2..12] Cardiovasc) (NNP:[13..22] Pharmacol) (.:[22..23] .) (CD:[24..28] 1990) (CC:[29..35] Sep;16) (-LRB-:[35..36] -LRB-) (CD:[36..37] 3) (-RRB-:[37..38] -RRB-) (CD:[38..45] :438-43) (.:[45..46] .))) ;sentence 1 Span:52..219 ;Cytochrome P450-dependent arachidonic acid metabolites, 19- and ;20-hydroxyeicosatetraenoic acids, enhance sodium-potassium ATPase activity in ; vascular smooth muscle. ;[52..67]:cyp450:"Cytochrome P450" ;[78..106]:substance:"arachidonic acid metabolites" ;[108..111]...[120..149]:substance:"19-"..."hydroxyeicosatetraenoic acids" ;[117..149]:substance:"20-hydroxyeicosatetraenoic acids" ;[159..182]:substance:"sodium-potassium ATPase" (SENT (S-HLN (NP-SBJ (NP (ADJP (NML (NN:[52..62] Cytochrome) (NN:[63..67] P450)) (HYPH:[67..68] -) (JJ:[68..77] dependent)) (NML (JJ:[78..89] arachidonic) (NN:[90..94] acid)) (NNS:[95..106] metabolites)) (,:[106..107] ,) (NP (NP (ADJP (CD:[108..110] 19) (HYPH:[110..111] -) (ADJP-1 (-NONE-:[111..111] *P*))) (NML-2 (-NONE-:[111..111] *P*))) (CC:[112..115] and) (NP (ADJP (CD:[117..119] 20) (HYPH:[119..120] -) (ADJP-1 (JJ:[120..143] hydroxyeicosatetraenoic))) (NML-2 (NNS:[144..149] acids))))) (,:[149..150] ,) (VP (VBP:[151..158] enhance) (NP (NML (NN:[159..165] sodium) (HYPH:[165..166] -) (NN:[166..175] potassium)) (NN:[176..182] ATPase) (NN:[183..191] activity)) (PP-LOC (IN:[192..194] in) (NP (JJ:[196..204] vascular) (JJ:[205..211] smooth) (NN:[212..218] muscle)))) (.:[218..219] .))) ;section 2 Span:223..283 ;Escalante B, Sessa WC, Falck JR, Yadagiri P, Schwartzman ML. (SEC (FRAG (NNP:[223..232] Escalante) (NNP:[233..234] B) (,:[234..235] ,) (NNP:[236..241] Sessa) (NNP:[242..244] WC) (,:[244..245] ,) (NNP:[246..251] Falck) (NNP:[252..254] JR) (,:[254..255] ,) (NNP:[256..264] Yadagiri) (NNP:[265..267] P,) (NNP:[268..279] Schwartzman) (NNP:[280..282] ML) (.:[282..283] .))) ;section 3 Span:287..356 ;Department of Pharmacology, New York Medical College, Valhalla 10595. (SEC (FRAG (NNP:[287..297] Department) (IN:[298..300] of) (NNP:[301..313] Pharmacology) (,:[313..314] ,) (NNP:[315..318] New) (NNP:[319..323] York) (NNP:[324..331] Medical) (NNP:[332..339] College) (,:[339..340] ,) (NNP:[341..349] Valhalla) (CD:[350..355] 10595) (.:[355..356] .))) ;sentence 4 Span:360..475 ;Several cytochrome P450-dependent arachidonic acid metabolites have been ;shown to affect Na+,K(+)-ATPase activity. ;[368..383]:cyp450:"cytochrome P450" ;[394..422]:substance:"arachidonic acid metabolites" ;[450..465]:substance:"Na+,K(+)-ATPase" (SENT (S (NP-SBJ-1 (JJ:[360..367] Several) (ADJP (NML (NN:[368..378] cytochrome) (NN:[379..383] P450)) (HYPH:[383..384] -) (JJ:[384..393] dependent)) (NML (JJ:[394..405] arachidonic) (NN:[406..410] acid)) (NNS:[411..422] metabolites)) (VP (VBP:[423..427] have) (VP (VBN:[428..432] been) (VP (VBN:[433..438] shown) (S (NP-SBJ-1 (-NONE-:[438..438] *)) (VP (TO:[440..442] to) (VP (VB:[443..449] affect) (NP (NN:[450..465] Na+,K-LRB-+-RRB--ATPase) (NN:[466..474] activity)))))))) (.:[474..475] .))) ;sentence 5 Span:476..683 ;In the present study, we tested the effect of omega- and omega - ;1-hydroxylated products, i.e., 19- and 20-hydroxyeicosatetraenoic acids (19- ;and 20-HETE), on the K-induced relaxation in rat aortic rings. ;[557..565]:substance:"products" ;[573..576]...[585..614]:substance:"19-"..."hydroxyeicosatetraenoic acids" ;[582..614]:substance:"20-hydroxyeicosatetraenoic acids" ;[616..619]...[627..631]:substance:"19-"..."HETE" ;[624..631]:substance:"20-HETE" ;[641..642]:substance:"K" (SENT (S (PP-LOC (IN:[476..478] In) (NP (DT:[479..482] the) (JJ:[483..490] present) (NN:[491..496] study))) (,:[496..497] ,) (NP-SBJ (PRP:[498..500] we)) (VP (VBD:[501..507] tested) (NP (NP (DT:[508..511] the) (NN:[512..518] effect)) (PP (IN:[520..522] of) (NP (NP (NP (ADJP (SYM:[523..528] omega) (HYPH:[528..529] -) (ADJP-4 (-NONE-:[529..529] *P*))) (NML-5 (-NONE-:[529..529] *P*))) (CC:[530..533] and) (NP (ADJP (SYM:[534..539] omega) (HYPH:[540..541] -) (CD:[542..543] 1) (HYPH:[543..544] -) (ADJP-4 (VBN:[544..556] hydroxylated))) (NML-5 (NNS:[557..565] products)))) (,:[565..566] ,) (NP (ADVP (FW:[567..571] i.e.)) (,:[571..572] ,) (NP (NP (NP (ADJP (CD:[573..575] 19) (HYPH:[575..576] -) (ADJP-2 (-NONE-:[576..576] *P*))) (NML-3 (-NONE-:[576..576] *P*))) (CC:[577..580] and) (NP (ADJP (CD:[582..584] 20) (HYPH:[584..585] -) (ADJP-2 (JJ:[585..608] hydroxyeicosatetraenoic))) (NML-3 (NNS:[609..614] acids)))) (NP (-LRB-:[615..616] -LRB-) (NP (CD:[616..618] 19) (HYPH:[618..619] -) (NML-1 (-NONE-:[619..619] *P*))) (CC:[620..623] and) (NP (CD:[624..626] 20) (HYPH:[626..627] -) (NML-1 (NN:[627..631] HETE))) (-RRB-:[631..632] -RRB-)))))) (,:[632..633] ,) (PP (IN:[634..636] on) (NP (NP (DT:[637..640] the) (ADJP (NN:[641..642] K) (HYPH:[642..643] -) (VBN:[643..650] induced)) (NN:[651..661] relaxation)) (PP-LOC (IN:[663..665] in) (NP (NN:[666..669] rat) (JJ:[670..676] aortic) (NNS:[677..682] rings))))))) (.:[682..683] .))) ;sentence 6 Span:684..811 ;19-HETE and 20-HETE increased the magnitude of the potassium-induced ;relaxation in a dose-dependent fashion (10(-7)-10(-5) M). ;[684..691]:substance:"19-HETE" ;[696..703]:substance:"20-HETE" ;[736..745]:substance:"potassium" ;[794..807]:quantitative-value:"10(-7)-10(-5)" ;[808..809]:quantitative-units:"M" (SENT (S (NP-SBJ (NN:[684..691] 19-HETE) (CC:[692..695] and) (NN:[696..703] 20-HETE)) (VP (VBD:[704..713] increased) (NP (NP (DT:[714..717] the) (NN:[718..727] magnitude)) (PP (IN:[728..730] of) (NP (DT:[731..734] the) (ADJP (NN:[736..745] potassium) (HYPH:[745..746] -) (VBN:[746..753] induced)) (NN:[754..764] relaxation)))) (PP-MNR (IN:[765..767] in) (NP (DT:[768..769] a) (ADJP (NN:[770..774] dose) (HYPH:[774..775] -) (JJ:[775..784] dependent)) (NN:[785..792] fashion))) (PRN (-LRB-:[793..794] -LRB-) (PRN (QP (CD:[794..800] 10-LRB--7-RRB-) (HYPH:[800..801] -) (CD:[801..807] 10-LRB--5-RRB-)) (NN:[808..809] M)) (-RRB-:[809..810] -RRB-))) (.:[810..811] .))) ;sentence 7 Span:812..920 ;The inhibitory effect of ouabain on the potassium-induced relaxation was ;reversed by both 19- and 20-HETE. ;[838..845]:substance:"ouabain" ;[853..862]:substance:"potassium" ;[904..907]...[915..919]:substance:"19-"..."HETE" ;[912..919]:substance:"20-HETE" (SENT (S (NP-SBJ-2 (NP (DT:[812..815] The) (JJ:[817..827] inhibitory) (NN:[828..834] effect)) (PP (IN:[835..837] of) (NP (NN:[838..845] ouabain))) (PP (IN:[846..848] on) (NP (DT:[849..852] the) (ADJP (NN:[853..862] potassium) (HYPH:[862..863] -) (VBN:[863..870] induced)) (NN:[871..881] relaxation)))) (VP (VBD:[882..885] was) (VP (VBN:[886..894] reversed) (NP-2 (-NONE-:[894..894] *)) (PP (IN:[895..897] by) (NP-LGS (CC:[899..903] both) (NML (CD:[904..906] 19) (HYPH:[906..907] -) (NML-1 (-NONE-:[907..907] *P*))) (CC:[908..911] and) (NML (CD:[912..914] 20) (HYPH:[914..915] -) (NML-1 (NN:[915..919] HETE))))))) (.:[919..920] .))) ;sentence 8 Span:921..1041 ;In addition, indomethacin fully inhibited the stimulatory effect of 19- and ;20-HETE on relaxation induced by potassium. ;[934..946]:substance:"indomethacin" ;[990..993]...[1001..1005]:substance:"19-"..."HETE" ;[998..1005]:substance:"20-HETE" ;[1031..1040]:substance:"potassium" (SENT (S (PP (IN:[921..923] In) (NP (NN:[924..932] addition))) (,:[932..933] ,) (NP-SBJ (NN:[934..946] indomethacin)) (ADVP (RB:[947..952] fully)) (VP (VBD:[953..962] inhibited) (NP (NP (DT:[963..966] the) (JJ:[967..978] stimulatory) (NN:[980..986] effect)) (PP (IN:[987..989] of) (NP (NP (CD:[990..992] 19) (HYPH:[992..993] -) (NML-1 (-NONE-:[993..993] *P*))) (CC:[994..997] and) (NP (CD:[998..1000] 20) (HYPH:[1000..1001] -) (NML-1 (NN:[1001..1005] HETE))))) (PP (IN:[1006..1008] on) (NP (NP (NN:[1009..1019] relaxation)) (VP (VBN:[1020..1027] induced) (NP (-NONE-:[1027..1027] *)) (PP (IN:[1028..1030] by) (NP-LGS (NN:[1031..1040] potassium)))))))) (.:[1040..1041] .))) ;sentence 9 Span:1042..1120 ;Vascular ouabain-sensitive 86Rb uptake was also increased by 19- and ;20-HETE. ;[1052..1059]:substance:"ouabain" ;[1070..1074]:substance:"86Rb" ;[1104..1107]...[1115..1119]:substance:"19-"..."HETE" ;[1112..1119]:substance:"20-HETE" (SENT (S (NP-SBJ-2 (JJ:[1042..1050] Vascular) (ADJP (NN:[1052..1059] ouabain) (HYPH:[1059..1060] -) (JJ:[1060..1069] sensitive)) (NN:[1070..1074] 86Rb) (NN:[1075..1081] uptake)) (VP (VBD:[1082..1085] was) (ADVP (RB:[1086..1090] also)) (VP (VBN:[1091..1100] increased) (NP-2 (-NONE-:[1100..1100] *)) (PP (IN:[1101..1103] by) (NP-LGS (NP (CD:[1104..1106] 19) (HYPH:[1106..1107] -) (NML-1 (-NONE-:[1107..1107] *P*))) (CC:[1108..1111] and) (NP (CD:[1112..1114] 20) (HYPH:[1114..1115] -) (NML-1 (NN:[1115..1119] HETE))))))) (.:[1119..1120] .))) ;sentence 10 Span:1121..1276 ;These observations suggest that 19- and 20-HETE stimulate vascular ;Na+,K(+)-ATPase via their conversion by cyclooxygenase to prostaglandin-like ;material. ;[1154..1157]...[1165..1169]:substance:"19-"..."HETE" ;[1162..1169]:substance:"20-HETE" ;[1189..1204]:substance:"Na+,K(+)-ATPase" ;[1230..1244]:substance:"cyclooxygenase" ;[1248..1261]:substance:"prostaglandin" (SENT (S (NP-SBJ (DT:[1121..1126] These) (NNS:[1128..1140] observations)) (VP (VBP:[1141..1148] suggest) (SBAR (IN:[1149..1153] that) (S (NP-SBJ (NP (CD:[1154..1156] 19) (HYPH:[1156..1157] -) (NML-1 (-NONE-:[1157..1157] *P*))) (CC:[1158..1161] and) (NP (CD:[1162..1164] 20) (HYPH:[1164..1165] -) (NML-1 (NN:[1165..1169] HETE)))) (VP (VBP:[1170..1179] stimulate) (NP (JJ:[1180..1188] vascular) (NN:[1189..1204] Na+,K-LRB-+-RRB--ATPase)) (PP-MNR (IN:[1205..1208] via) (NP (NP (PRP$:[1210..1215] their) (NN:[1216..1226] conversion)) (PP (IN:[1227..1229] by) (NP (NN:[1230..1244] cyclooxygenase))) (PP (TO:[1245..1247] to) (NP (ADJP (NN:[1248..1261] prostaglandin) (HYPH:[1261..1262] -) (JJ:[1262..1266] like)) (NN:[1267..1275] material))))))))) (.:[1275..1276] .))) ;section 11 Span:1280..1324 ;PMID: 1700215 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1280..1284] PMID) (::[1284..1285] :) (CD:[1286..1293] 1700215) (NN:[1294..1295] -LSB-) (NNP:[1295..1301] PubMed) (::[1302..1303] -) (NN:[1304..1311] indexed) (IN:[1312..1315] for) (NNP:[1316..1324] MEDLINE-RSB-)))